KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000

Transaction summary

Transaction and post-transaction values based connected SEC Form 4 weighted mean acquisition terms of $26.78 connected May 27, 2026.

Key questions

• How does the size of this transaction comparison to anterior trades by Christopher Yea?
  This is lone the 2nd open-market merchantability reported by Yea, with the erstwhile merchantability involving 39,886 shares; however, the bulk of humanities trades person been administrative events, not outright sales.

• What is the derivative discourse for this transaction?
  The 33,800 shares sold were acquired done the workout of vested options and were instantly disposed of, resulting successful nary nett summation to Yea's semipermanent communal banal holdings.

• What is Yea's remaining vulnerability to KalVista Pharmaceuticals equity?
  Following this transaction, Yea holds 229,918 shares directly, valued astatine astir $6.16 cardinal arsenic of May 27, 2026, with nary remaining exercisable options oregon indirect holdings.

• Is determination grounds of an accelerating selling signifier oregon a displacement successful liquidity cadence?
  Despite nett income reducing full nonstop holdings by 28.84% implicit the past year, the gait and size of outright income stay limited, and caller transactions bespeak diminished disposable capableness alternatively than an escalation successful discretionary selling.

Company overview

* 1-year terms alteration calculated utilizing May 29th, 2026 arsenic the notation date.

Company snapshot

• Develops and commercializes tiny molecule plasma kallikrein inhibitors, with a pipeline focused connected hereditary angioedema (HAE) and diabetic macular edema (DME).

• Operates arsenic a commercial-stage biotechnology institution processing cause candidates for hereditary angioedema (HAE) and diabetic macular edema (DME).

• Targets patients with uncommon diseases, peculiarly those affected by HAE and DME.

KalVista Pharmaceuticals, Inc. is simply a commercial-stage biotechnology institution specializing successful the improvement of oral plasma kallikrein inhibitors for uncommon and underserved diseases. The institution leverages a focused R&D strategy to beforehand caller therapies for hereditary angioedema and diabetic macular edema, aiming to code important unmet aesculapian needs.